An observational study in Traumatic Brain Injury, sponsored by University of Pennsylvania. Active, not recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by University of Pennsylvania · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Brain Injuries, Traumatic by University of Pennsylvania — 3 open to participants now, 6 under way, none of them phase 3. Brain Injuries, Traumatic · University of Pennsylvania.
Among the 12 studies in Brain Injuries, Traumatic by University of Pennsylvania, this one is one of 3 that started in 2022, is one of 5 observational ones, and was the 8th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →3 of the 12 studies in Brain Injuries, Traumatic by University of Pennsylvania are open now, in 1 country. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18–70
University of Pennsylvania · Sites in United States
Ages 18–65 · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 116 across 558 observational studies indexed under Brain Injuries, Traumatic.
Median enrollment 38 across the 7 interventional studies, 300 across the 5 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
3 of the studies in Brain Injuries, Traumatic by University of Pennsylvania that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05201833University of PennsylvaniaTRACK-TBI Longitudinal Biomarker Study | 2026-12-30 |
| NCT04565119University of PennsylvaniaBiomarkers in the Brain Oxygen Optimization in Severe Traumatic Brain Injury Trial | 2026-12-31 |
| NCT05725993University of PennsylvaniaLongitudinal Assessment of Traumatic Microvascular Injury-2 | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies in Brain Injuries, Traumatic by University of Pennsylvania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overarching goal of this study is to improve understanding of the long-range natural history of TBI by extending follow-up of a previously enrolled cohort (TRACK-TBI) beyond the first 12 months after injury.
This longitudinal observational study is part of the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) initiative, a multi-institutional project designed to characterize the acute and longer-term clinical, neuroimaging, and blood biomarker features of TBI. TRACK-TBI enrolled TBI patients at 18 Level 1 Trauma Centers in the US, across the age and injury spectrum. This study will extend the follow-up period for TRACK-TBI participants. The extensive clinical, imaging, and biomarker data that has already been collected in these TRACK-TBI participants, in combination with the extended longitudinal data, will allow for the identification of risk factors, co-morbidities, and prognostic biomarkers of TBI. Consequently, the extension of study follow-up will help to determine negative neurological and psychological outcomes of individuals who experienced a TBI compared to healthy and orthopedic controls.
TBI is a complex disease process, in which diverse injury subtypes and multiple molecular mechanisms overlap. There is a need to identify and measure these subtypes, in order to develop precision medicine approaches where specific pathobiological processes are targeted by mechanistically appropriate therapies. The absence of validated biomarkers in the neurotrauma field is a barrier to drug development in this area, and there are currently no disease-modifying therapies that limit the burden of TBI. Biomarkers specific for injury mechanisms should be identified to select participants for clinical trials of targeted therapies (prognostic biomarkers), as well as to confirm target engagement and biological efficacy (pharmacodynamic biomarkers).
Traumatic axonal injury (TAI) is a common pathologic consequence of TBI, and underlies some of the most disabling consequences of injury, including cognitive and affective problems. TAI progresses for years after injury in a subset of patients, and is a key mechanism for long-term neurodegeneration after TBI. Recent breakthroughs in pre-clinical models indicate that novel therapeutic interventions, including strategies such as targeting the mitochondrial transition pore, or promoting axonal maintenance factors are effective in promoting resilience of injured axons and improving neurologic outcome after experimental TBI. Translation of such promising therapies into clinical trials will require prognostic biomarkers that can measure TAI in individual patients, so they can be selected for early phase studies of axon-protective therapies, as well pharmacodynamic biomarkers than can measure the biologic efficacy of such treatments. Currently, the best biomarker for TAI is fractional anisotropy (FA) and mean diffusivity (MD) of white matter tracts, measured using diffusion tensor imaging (DTI) MRI. This technique, while robust, is poorly suited for dynamic longitudinal assessments, and measures the end-result of axonal degeneration, rather than an early step in the neurodegenerative process. Recently, the ability to assay axonal proteins in peripheral blood has made it potentially feasible to assess of TAI rapidly, inexpensively, and longitudinally. The axonal protein that holds the most promise as a biomarker of axonal degeneration is neurofilament light chain (NF-L). This project aims to address the gaps in the existing literature regarding specific biomarkers for injury mechanisms and outcomes following TBI. Furthermore, it is likely that a sophisticated understanding of the subtypes and molecular mechanisms of TBI will be required to successfully develop therapies to treat these subtypes.
Participants enrolled in TRACK-TBI
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must complete at least one Longitudinal Telephone Assessment and fall into one of the following groups:
Ability of participant or legally authorized representative to provide
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TRACK-TBI participants may complete up to three annual telephone calls to assess outcome status. These assessments will determine eligibility for the in-person study visit.
Behavioral: Telephone Outcome Assessment
Participants who demonstrate decision-making capacity will be asked to complete the Comprehensive Assessment Battery (CAB). The CAB in-person is comprised of measures of cognition (i.e. attention, memory, information processing speed, executive functions), mood (i.e., depression, anxiety), social participation, subjective well-being, post-traumatic stress, interviews, global functional status measures, and a COVID-19 questionnaire.
Behavioral: Telephone Outcome Assessment · Behavioral: In-Person Outcome Assessment · Procedure: 3T Magnetic Resonance Imaging (MRI) · Procedure: Blood Draw
Participants who do not have decision-making capacity will be asked to complete a modified assessment battery, called the Abbreviated Assessment Battery (AAB). The AAB in-person assessment will administer the Speech Intelligibility, GOAT, and CAP and/or CRS-R to study participants.
Behavioral: Telephone Outcome Assessment · Behavioral: In-Person Outcome Assessment · Procedure: 3T Magnetic Resonance Imaging (MRI) · Procedure: Blood Draw
Assessments will be administered over the telephone to evaluate participant outcome status
Assessments will be administered to evaluate participant outcome status
Participants will be asked to complete a 3T MRI
Blood Draw for Plasma, DNA, Serum, RNA
Glasgow Outcome Scale Extended (GOSE)
The GOSE provides an overall measure of functional status based on information on cognition, independence, employability, and social/community participation collected via structured interview. Individuals are described by one of the eight outcome categories: Dead (1); Vegetative State (2); Lower Severe Disability (3); Upper Severe Disability (4); Lower Moderate Disability (5); Upper Moderate Disability (6); Lower Good Recovery (7) and Upper Good Recovery (8). Good Recovery is defined as a score of 7-8, Moderate Disability is defined by a score of 5-6 and Severe Disability is defined by a score of 3-4.
Time frame: ~4-6 years post-injury
Serum NF-L (neurofilament light chain)
Using advanced blood-based assay platforms, levels of blood biomarkers neurofilament light chain (NF-L) will be measured to validate the utility as a biomarkers for traumatic axonal injury (TAI).
Time frame: ~4-6 years post-injury
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.
Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 57 months is above that.
Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.